|
RZLT | Rezolute, Inc. |
|
|
RZLT | Rezolute, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.55 |
| Leverage | 11.09% |
| Market Cap | $ 182.7m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -70.6m |
| Margin | -3215.01% |
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City, California.